AML Advanced | AML Relapsed | AML refractory | Acute lymphocytic leukemia Advanced | Acute lymphocytic leukemia Relapsed | Acute lymphocytic leukaemia refractory | MYELODYSPLASTIC SYNDROME Advanced | MYELODYSPLASTIC SYNDROME Relapsed | MYELODYSPLASTIC SYNDROME refractory | CMML Advanced | CMML Relapsed | CMML refractory | peripheral blood Blast count procedure | Bone Marrow Blast count procedure | Blast Phase | Primary Myelofibrosis | Chronic Lymphocytic Leukemia | Leukemia, T-Cell | Mantle cell lymphoma
Item
1. patients with advanced, relapsed or refractory: acute leukemias (aml, all), mds, cmml in transformation with greater than or equal to 10% peripheral blood/bone marrow blasts, cml in blastic phase, agnogenic myeloid metaplasia (amm), cll, t-cell leukemia, or mantle cell lymphoma.
boolean
C0023467 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C0023467 (UMLS CUI [2,1])
C0205336 (UMLS CUI [2,2])
C0023467 (UMLS CUI [3,1])
C0205269 (UMLS CUI [3,2])
C0023449 (UMLS CUI [4,1])
C0205179 (UMLS CUI [4,2])
C0023449 (UMLS CUI [5,1])
C0205336 (UMLS CUI [5,2])
C4049242 (UMLS CUI [6])
C3463824 (UMLS CUI [7,1])
C0205179 (UMLS CUI [7,2])
C3463824 (UMLS CUI [8,1])
C0205336 (UMLS CUI [8,2])
C3463824 (UMLS CUI [9,1])
C0205269 (UMLS CUI [9,2])
C0023480 (UMLS CUI [10,1])
C0205179 (UMLS CUI [10,2])
C0023480 (UMLS CUI [11,1])
C0205336 (UMLS CUI [11,2])
C0023480 (UMLS CUI [12,1])
C0205269 (UMLS CUI [12,2])
C0229664 (UMLS CUI [13,1])
C0523113 (UMLS CUI [13,2])
C0005953 (UMLS CUI [14,1])
C0523113 (UMLS CUI [14,2])
C0005699 (UMLS CUI [15])
C0001815 (UMLS CUI [16])
C0023434 (UMLS CUI [17])
C0023492 (UMLS CUI [18])
C0334634 (UMLS CUI [19])
Serum total bilirubin measurement | Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Creatinine measurement, serum | Organ leukemia Involvement with | Gilbert Disease
Item
2. serum bilirubin <= 2 mg/dl, sgot or sgpt < 3 upper limit of normal, serum creatinine <= 2 mg/dl, unless considered due to organ leukemic involvement or gilbert's syndrome
boolean
C1278039 (UMLS CUI [1])
C0201899 (UMLS CUI [2])
C0201836 (UMLS CUI [3])
C0201976 (UMLS CUI [4])
C0178784 (UMLS CUI [5,1])
C0023418 (UMLS CUI [5,2])
C1314939 (UMLS CUI [5,3])
C0017551 (UMLS CUI [6])
RAD 001 Effect Fetus Unknown | mRNA Translation inhibitors | Teratogenesis | Childbearing Potential Contraceptive methods | Hormonal contraception | Contraception, Barrier | Sexual Abstinence | Gender Contraceptive methods | Patient currently pregnant Informing Treating Physician
Item
3. the effects of rad001 on the developing human fetus are unknown. for this reason and because inhibitors of mrna translation are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation. should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
boolean
C0962969 (UMLS CUI [1,1])
C1280500 (UMLS CUI [1,2])
C0015965 (UMLS CUI [1,3])
C0439673 (UMLS CUI [1,4])
C0597295 (UMLS CUI [2,1])
C0243077 (UMLS CUI [2,2])
C0232910 (UMLS CUI [3])
C3831118 (UMLS CUI [4,1])
C0700589 (UMLS CUI [4,2])
C2985296 (UMLS CUI [5])
C0004764 (UMLS CUI [6])
C0036899 (UMLS CUI [7])
C0079399 (UMLS CUI [8,1])
C0700589 (UMLS CUI [8,2])
C0549206 (UMLS CUI [9,1])
C0700287 (UMLS CUI [9,2])
C1710470 (UMLS CUI [9,3])
Informed Consent
Item
4. ability to understand and the willingness to sign a written informed consent document.
boolean
C0021430 (UMLS CUI [1])
Cytotoxic Chemotherapy | hydroxyurea | Adrenal Cortex Hormones | Therapeutic radiology procedure
Item
1. patients who have had cytotoxic chemotherapy (other than hydroxyurea or corticosteroids) or radiotherapy within 7 days prior to entering the study.
boolean
C0677881 (UMLS CUI [1])
C0020402 (UMLS CUI [2])
C0001617 (UMLS CUI [3])
C1522449 (UMLS CUI [4])
Cytotoxic agent Investigational
Item
2. patients may not be receiving any other cytotoxic investigational agents.
boolean
C0304497 (UMLS CUI [1,1])
C1517586 (UMLS CUI [1,2])
Allergic Reaction Compound RAD 001 Similar | RAD 001 | Hypersensitivity everolimus | Hypersensitivity Sirolimus | Hypersensitivity Pharmaceutical Excipient | Hypersensitivity Butylated Hydroxytoluene | Hypersensitivity Magnesium stearate | Hypromellose allergy | Hypersensitivity Crospovidone | Hypersensitivity Lactose
Item
3. history of allergic reactions attributed to compounds of similar chemical or biologic composition to rad001. rad001 must not be administered to patients with known hypersensitivity to everolimus, sirolimus or to any of its excipients. excipients include butylated hydroxytoluene, magnesium stearate, hydroxypropylmethyl-cellulose, crospovidone, and lactose.
boolean
C1527304 (UMLS CUI [1,1])
C1706082 (UMLS CUI [1,2])
C0962969 (UMLS CUI [1,3])
C2348205 (UMLS CUI [1,4])
C0962969 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0541315 (UMLS CUI [3,2])
C0020517 (UMLS CUI [4,1])
C0072980 (UMLS CUI [4,2])
C0020517 (UMLS CUI [5,1])
C0015237 (UMLS CUI [5,2])
C0020517 (UMLS CUI [6,1])
C0006507 (UMLS CUI [6,2])
C0020517 (UMLS CUI [7,1])
C0126791 (UMLS CUI [7,2])
C0571249 (UMLS CUI [8])
C0020517 (UMLS CUI [9,1])
C0728803 (UMLS CUI [9,2])
C0020517 (UMLS CUI [10,1])
C0022949 (UMLS CUI [10,2])
Illness Uncontrolled | Communicable Diseases | Symptomatic congestive heart failure | Angina, Unstable | Cardiac Arrhythmia | Mental disorder Protocol Compliance Limited | social situation Protocol Compliance Limited
Item
4. uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
boolean
C0221423 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0009450 (UMLS CUI [2])
C0742758 (UMLS CUI [3])
C0002965 (UMLS CUI [4])
C0003811 (UMLS CUI [5])
C0004936 (UMLS CUI [6,1])
C0525058 (UMLS CUI [6,2])
C0439801 (UMLS CUI [6,3])
C0748872 (UMLS CUI [7,1])
C0525058 (UMLS CUI [7,2])
C0439801 (UMLS CUI [7,3])
Pregnancy | RAD 001 | Teratogenesis | Abortifacient Effect | Adverse event Risk | Breast Feeding Discontinued
Item
5. pregnant women are excluded from this study because rad001 has a potential for teratogenic or abortifacient effects. because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with rad001, breastfeeding should be discontinued if the mother is treated with rad001.
boolean
C0032961 (UMLS CUI [1])
C0962969 (UMLS CUI [2])
C0232910 (UMLS CUI [3])
C3179338 (UMLS CUI [4])
C0877248 (UMLS CUI [5,1])
C0035647 (UMLS CUI [5,2])
C0006147 (UMLS CUI [6,1])
C1444662 (UMLS CUI [6,2])